Literature DB >> 11022789

Marek's disease herpesvirus transforming protein MEQ: a c-Jun analogue with an alternative life style.

J L Liu1, H J Kung.   

Abstract

In order to adapt to and to cope with an often hostile host environment, many viruses have evolved to encode products that are homologous to cellular proteins. These proteins exploit the existing host machinery and allow viruses to readily integrate into the host functional network. As a result, viruses are able to maneuver their journey seemingly effortlessly inside the host cell to achieve ultimate survival. Such molecular mimicries sometime go overboard, allowing viruses to overtake the cellular pathways or evade the immune system as do many of the retroviral oncogenes. Retroviral oncogenes are derived directly from host genes, and they are virtually identical to host genes in sequences except those mutations that make them unregulatable by host. Oncogenic herpesviruses also encode oncogenes, or transforming genes, which have independently evolved and are distantly related to host genes. However, these genes do share consensus structural motifs with cellular genes involved in cell growth and apoptosis and are functional analogues to host genes. The Marek's disease virus oncoprotein, MEQ, is one such example. MEQ is a basic region-leucine zipper (bZIP) transactivator which shares extensive homology with the Jun/Fos family of transcription factors within the bZIP domain, but not in other regions. Like all other bZIP proteins, MEQ is capable of dimerizing with itself and with a variety of bZIP partners including c-Jun, B-Jun, c-Fos, CREB, ATF-1, ATF-2, and SNF. MEQ-Jun heterodimers bind to a TRE/CRE-like sequence in the meq promoter region and have been shown to up-regulate MEQ expression in both chicken embryo fibroblasts and F9 cells. In addition, the bZIP and transactivation domains are interchangeable between MEQ and c-Jun in terms of transforming potential; i.e. MEQ can functionally substitute for c-Jun. These properties enable MEQ to engage in host cell processes by disguising itself as c-Jun. On the other hand, there are properties of MEQ notably different from c-Jun, which include its capability to bind RNA, to bind a CACAC-bent DNA structure as a homodimer, to inhibit apoptosis, and to interact with CDK2. MEQ's subcellular localization in the nucleolus and coiled body, is also different from Jun/Fos family of transactivators. These unique features may provide the MEQ with additional facility in regulating MDV replication, establishing latency, and cellular transformation. In this review, we will attempt to summarize the past research progress on MDV meq, with a focused on the similarities and differences between MEQ and cellular proteins, and between MEQ and other viral oncoproteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022789

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.198


  135 in total

1.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.

Authors:  J Hauber; M H Malim; B R Cullen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Oncogenic potential of the adenovirus E4orf6 protein.

Authors:  M Moore; N Horikoshi; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

4.  Subcellular distribution of human immunodeficiency virus type 1 Rev and colocalization of Rev with RNA splicing factors in a speckled pattern in the nucleoplasm.

Authors:  K H Kalland; A M Szilvay; E Langhoff; G Haukenes
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Intracellular localization of the herpes simplex virus type 1 major transcriptional regulatory protein, ICP4, is affected by ICP27.

Authors:  Z Zhu; P A Schaffer
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  The nuclear matrix protein NMP-1 is the transcription factor YY1.

Authors:  B Guo; P R Odgren; A J van Wijnen; T J Last; J Nickerson; S Penman; J B Lian; J L Stein; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  Reversible nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 and hsp70 proteins after exposure to heat shock or cell density congestion.

Authors:  L Szekely; W Q Jiang; K Pokrovskaja; K G Wiman; G Klein; N Ringertz
Journal:  J Gen Virol       Date:  1995-10       Impact factor: 3.891

8.  Human cytomegalovirus IE1 and IE2 proteins block apoptosis.

Authors:  H Zhu; Y Shen; T Shenk
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

9.  The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein.

Authors:  M Dundr; G H Leno; M L Hammarskjöld; D Rekosh; C Helga-Maria; M O Olson
Journal:  J Cell Sci       Date:  1995-08       Impact factor: 5.285

10.  Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies.

Authors:  T Carvalho; J S Seeler; K Ohman; P Jordan; U Pettersson; G Akusjärvi; M Carmo-Fonseca; A Dejean
Journal:  J Cell Biol       Date:  1995-10       Impact factor: 10.539

View more
  22 in total

1.  Marek's disease virus unique genes pp38 and pp24 are essential for transactivating the bi-directional promoters for the 1.8 kb mRNA transcripts.

Authors:  Jiabo Ding; Zhizhong Cui; Lucy F Lee
Journal:  Virus Genes       Date:  2007-07-06       Impact factor: 2.332

2.  Nuclear localization and dynamic properties of the Marek's disease virus oncogene products Meq and Meq/vIL8.

Authors:  Jonathan M Anobile; Vaithilingaraja Arumugaswami; Danielle Downs; Kirk Czymmek; Mark Parcells; Carl J Schmidt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Marek's disease virus encodes MicroRNAs that map to meq and the latency-associated transcript.

Authors:  Joan Burnside; Erin Bernberg; Amy Anderson; Cheng Lu; Blake C Meyers; Pamela J Green; Neeta Jain; Grace Isaacs; Robin W Morgan
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Analysis of transcriptional activities of the Meq proteins present in highly virulent Marek's disease virus strains, RB1B and Md5.

Authors:  Shiro Murata; Tsukasa Okada; Rika Kano; Yuko Hayashi; Tomoyuki Hashiguchi; Misao Onuma; Satoru Konnai; Kazuhiko Ohashi
Journal:  Virus Genes       Date:  2011-04-19       Impact factor: 2.332

5.  Sequence analysis of the Meq gene in the predominant Marek's disease virus strains isolated in China during 2006-2008.

Authors:  Yan-Ping Zhang; Chang-Jun Liu; Feng Zhang; Weisong Shi; Jingmei Li
Journal:  Virus Genes       Date:  2011-07-26       Impact factor: 2.332

6.  Large Maf Transcription Factors: Cousins of AP-1 Proteins and Important Regulators of Cellular Differentiation.

Authors:  Ying Yang; Ales Cvekl
Journal:  Einstein J Biol Med       Date:  2007

7.  Homodimerization of the Meq viral oncoprotein is necessary for induction of T-cell lymphoma by Marek's disease virus.

Authors:  Andrew C Brown; Lorraine P Smith; Lydia Kgosana; Susan J Baigent; Venugopal Nair; Martin J Allday
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

8.  Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells.

Authors:  Alon M Levy; Yoshihiro Izumiya; Peter Brunovskis; Liang Xia; Mark S Parcells; Sanjay M Reddy; Lucy Lee; Hong-Wu Chen; Hsing-Jien Kung
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Transcriptional profiling of Marek's disease virus genes during cytolytic and latent infection.

Authors:  Mohammad Heidari; Marianne Huebner; Dmitry Kireev; Robert F Silva
Journal:  Virus Genes       Date:  2008-02-12       Impact factor: 2.332

10.  Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma.

Authors:  Andrew C Brown; Venugopal Nair; Martin J Allday
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.